SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastastic colorectal carcinoma

DOI

These data support the main findings described in 'SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma'.

The data contains the results from the SUNRISE-CRC trial, registered on ClinicalTrials.gov (NCT03909724). In total 63 patients were randomized 1:1 between treatment with high-dose intermittent sunitinib (700mg Q2W) and trifluridine/tipiracil in the 3rd or 4th line treatment setting for mCRC. The trial was performed in five centers in the Netherlands.

Identifier
DOI https://doi.org/10.17026/LS/JLK0T3
Metadata Access https://lifesciences.datastations.nl/oai?verb=GetRecord&metadataPrefix=oai_datacite&identifier=doi:10.17026/LS/JLK0T3
Provenance
Creator J.B.E. Janssen ORCID logo; H.W.W. Verheul (ORCID: 0000-0001-5981-922X)
Publisher DANS Data Station Life Sciences
Contributor H.W.W. Verheul
Publication Year 2024
Funding Reference ZonMW ; Oncode
Rights DANS Licence; info:eu-repo/semantics/restrictedAccess; https://doi.org/10.17026/fp39-0x58
OpenAccess false
Contact H.W.W. Verheul (ErasmusMC)
Representation
Resource Type clinical trial data; Dataset
Format application/vnd.oasis.opendocument.spreadsheet
Size 7728; 8549; 16081; 7106; 11864; 23442; 48368; 19370; 16477; 12754
Version 2.0
Discipline Life Sciences; Medicine